Intravenous Ferric Derisomaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anemia in Pregnancy: A Randomized, Comparative Trial.

J Obstet Gynaecol CanJul 10, 2026 (epub)
Clinical ResearchObstetrics & GynecologyHematology

Sarah Smith, Shirmin Kader, Ryan Lett

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of intravenous ferric derisomaltose (FDM) compared to iron sucrose (IS) in treating iron deficiency anemia (IDA) in pregnant individuals. The study found no significant difference in the normalization of hemoglobin levels between the two treatments, although both resulted in improvements in hemoglobin and symptoms.

Key findings

  • No significant difference in normalization of hemoglobin between FDM and IS treatments.
  • Both treatments led to improvements in hemoglobin levels and participant symptoms.

Why it matters

Understanding the efficacy of different iron treatments in pregnancy is crucial for optimizing care in patients with iron deficiency anemia, a common condition that can affect maternal and fetal health.

What to keep in mind

The study was not adequately powered to detect differences in outcomes.

Source

PubMed · PMID 42431429

Published in J Obstet Gynaecol Can. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.